



UNITED STATES PATENT AND TRADEMARK OFFICE

C1C
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,328	12/09/2004	Jeffrey A.Smith	00789-05	7405
34444	7590	09/20/2005	EXAMINER	
UNIVERSITY OF VIRGINIA PATENT FOUNDATION 250 WEST MAIN STREET, SUITE 300 CHARLOTTESVILLE, VA 22902				KRISHNAN, GANAPATHY
		ART UNIT		PAPER NUMBER
		1623		

DATE MAILED: 09/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/517,328	SMITH ET AL.
	Examiner Ganapathy Krishnan	Art Unit 1623

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 09 December 2004.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-47 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1-47 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input checked="" type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. <u>9/9/2005</u> .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9 and 33-38 drawn to pharmaceutical compositions comprising compound of structure I.

Group II, claim(s) 10-12, 19-20 and 47, drawn to extract of tissues from Forsteronia refracta and method for preparing the extract.

Group III, claim(s) 13-16, drawn to a method of inhibiting Rsk activity with a compound of formula III.

Group IV, claim(s) 17-18, drawn to a method of screening for Rsk activity.

Group V, claims(s) 21-32, drawn to a method of treating a disease or a condition characterized by inappropriate Rsk activity.

Group VI, claims(s) 39-46, drawn to Method of detecting neoplastic cells.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT rule 13.1-13.3. PCT 13.1 states that the international application shall relate to one invention only or to a group of inventions linked as to form “a single general inventive concept”. PCT 13.2 indicates that such unity of invention is fulfilled only when there is a

“technical relationship” among those inventions involving one or more of the same or corresponding “special technical feature”.

In the instant Groups I-VI, a “technical relationship” corresponding to the special technical feature is lacking because the special feature for patentability of Groups I-VI are:

The special technical feature of Group I is considered to be compound of structural formula I.

The special technical feature of Group II is considered to be an extract from a specific plant species.

The special technical feature of Group III is a method of inhibiting Rsk activity.

The special technical feature of Group IV is a method of screening for Rsk activity.

The special technical feature of Group V is a method of treating a disease or a condition characterized by inappropriate Rsk activity.

The special technical feature of Group VI is method of detecting neoplastic cells.

Since the method of treating a disease or condition characterized by inappropriate activity is different from that of detecting neoplastic cells, screening for Rsk activity, inhibiting Rsk activity, compositions and extracts and involve different procedural steps they are not so uniquely linked to each other.

Because the groups are patentably distinct, the search for one group is not coextensive with the others and each must be searched independently and therefore would entail a burdensome search.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).


A telephone call was made to Mr. Rodney Sparks on September 9, 2005 to request an oral election to the above restriction requirement, but did not result in an election being made.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathy Krishnan whose telephone number is 571-272-0654. The examiner can normally be reached between 8.30am-5.00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

GK



JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600